STOCK COMPARISON
Pharma Reaserch Prod Co vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Pharma Reaserch Prod Co (214450) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees Pharma Reaserch Prod Co as the less overvalued of the two: Pharma Reaserch Prod Co trades at KRW 378,500 versus a fair value of KRW 308,302 (-19%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
Pharma Reaserch Prod Co
214450.KQ · KRW · Health Care
-19%
upside to fair value
overvalued
PriceKRW 378,500
Fair ValueKRW 308,302
Quality78/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-44%
upside to fair value
overvalued
Price$496
Fair Value$279
Quality79/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Pharma Reaserch Prod CoVertex Pharmaceuticals
Valuation
—P/E (TTM)28.8×
—P/S (TTM)10.06×
—P/B6.59×
—EV/EBITDA23.8×
—PEG1.72×
1.1%Dividend yield—
KRW 3,700Dividend per share—
Profitability
31%Net margin36%
39%Operating margin38%
27%Return on equity24%
14%Return on assets12%
Growth
25%Revenue growth (YoY)8%
40.2%Avg. growth/yr (3Y)10.6%
37.6%Avg. growth/yr (5Y)14.2%
Balance & size
0.00×Debt / equity0.03×
$2BMarket cap$123B
healthyGrowth qualityhealthy
Pharma Reaserch Prod Co leads: 7 to 1 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Pharma Reaserch Prod Coof which business quality 77 · market factors 30
Vertex Pharmaceuticalsof which business quality 77 · market factors 65
ProfitabilityMargins and returns on capital today
75
72
Quality GrowthAre margins and returns improving?
100
65
CashflowEarnings quality: real cash, not paper profit
79
79
Fin. StrengthBalance sheet, leverage, solvency risk
91
92
InvestmentDisciplined investing over empire-building
25
58
Low VolatilityCalm price path (market factor)
50
86
MomentumPrice trend over the last 3–12 months (market factor)
26
54
52W MomentumDistance to the 52-week high (market factor)
14
59
Net IssuanceBuybacks instead of dilution
73
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Pharma Reaserch Prod Co
DCF ModelsKRW 510,052
Earnings-BasedKRW 549,892
Dividend DiscountKRW 21,563
MultiplesKRW 298,626
Asset-BasedKRW 44,453
Growth DCFKRW 414,251
Economic ProfitKRW 291,407
Growth EarningsKRW 731,541
13 of 26 models see the stock below the current price.
Vertex Pharmaceuticals
DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692
18 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Pharma Reaserch Prod Co
Bear KRW 230,750Fair Value KRW 308,302Bull KRW 951,003
KRW 378,500 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$496 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Pharma Reaserch Prod Co · Health Care
Quality score78 · Top 25%
Fair value upside-19% · above median
Vertex Pharmaceuticals · Health Care
Quality score79 · Top 25%
Fair value upside-44% · below median
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees Pharma Reaserch Prod Co as the less overvalued of the two: Pharma Reaserch Prod Co trades at KRW 378,500 versus a fair value of KRW 308,302 (-19%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
Vertex Pharmaceuticals has the higher quality score (79/100).
See the full analysis →
More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Free · Top-25 report
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
